Nikolaj Torp
Overview
Explore the profile of Nikolaj Torp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Krag A, Torp N, Younossi Z, Israelsen M
Lancet Gastroenterol Hepatol
. 2025 Jan;
10(4):282-284.
PMID: 39855240
No abstract available.
3.
Hansen E, Torp N, Johansen S, Hansen J, Bergmann M, Hansen C, et al.
JHEP Rep
. 2024 Dec;
7(1):101200.
PMID: 39698234
Background & Aims: Quantifying alcohol intake is crucial for subclassifying participants with steatotic liver disease (SLD) and interpreting clinical trials of alcohol-related liver disease (ALD) and metabolic and alcohol-related liver...
4.
Lindvig K, Thorhauge K, Hansen J, Kjaergaard M, Hansen C, Johansen S, et al.
Lancet Gastroenterol Hepatol
. 2024 Dec;
10(1):55-67.
PMID: 39674225
Background: Clinically significant liver fibrosis is associated with future adverse events in patients with steatotic liver disease. We designed a software tool for detection of clinically significant liver fibrosis in...
5.
Torp N, Israelsen M, Krag A
Nat Rev Gastroenterol Hepatol
. 2024 Dec;
PMID: 39639157
The classification of steatotic liver disease (SLD) has evolved, incorporating all conditions characterized by hepatic lipid accumulation. SLD represents a continuum of disorders that are shaped by the dynamic factors...
6.
Nishijima S, Stankevic E, Aasmets O, Schmidt T, Nagata N, Keller M, et al.
Cell
. 2024 Nov;
188(1):222-236.e15.
PMID: 39541968
The microbiota in individual habitats differ in both relative composition and absolute abundance. While sequencing approaches determine the relative abundances of taxa and genes, they do not provide information on...
7.
Johansen S, Langkjaer S, Rasmussen D, Israelsen M, Torp N, Lindvig K, et al.
JHEP Rep
. 2024 Mar;
6(4):101016.
PMID: 38486819
Background & Aims: Infections are frequent in patients with cirrhosis and worsen prognosis. We evaluated the incidence of infections and their impact on decompensation and death in patients with early...
8.
Thorhauge K, Semmler G, Johansen S, Lindvig K, Kjaergaard M, Hansen J, et al.
J Hepatol
. 2024 Mar;
81(1):23-32.
PMID: 38428644
Background & Aims: Liver stiffness measurement (LSM) is recommended for disease prognostication and monitoring. We evaluated if LSM, using transient elastography, and LSM changes predict decompensation and mortality in patients...
9.
Torp N, Israelsen M, Coenraad M, Papp M, Shawcross D, Korenjak M, et al.
BMJ Open
. 2024 Feb;
14(2):e079309.
PMID: 38355195
Introduction: Human albumin is used in the treatment of complications of cirrhosis. However, the use of long-term human albumin administration is costly and resource demanding for both patients and healthcare...
10.
Israelsen M, Torp N, Johansen S, Hansen C, Hansen E, Thorhauge K, et al.
Lancet Gastroenterol Hepatol
. 2024 Jan;
9(3):218-228.
PMID: 38218202
Background: Steatotic liver disease is a new overarching term that includes metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related steatotic liver disease (MetALD), and alcohol-related liver disease (ALD)....